ANTIVIRAL ACTIVITY AND SAFETY OF ITMN-191 IN COMBINATION WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS (HCV)

被引：12
|
作者：
Forestier, N. [1 ]
Larrey, D. [2 ]
Marcellin, P. [3 ]
Benhamou, Y. [4 ]
Guyader, D. [5 ]
Bradford, W. [6 ]
Porter, S. [6 ]
Patat, A. [7 ]
Rouzier, R. [8 ]
Zeuzem, S. [1 ]
机构：
[1] Univ Frankfurt, Frankfurt, Germany
[2] CHU Montpellier, Montpellier, France
[3] Hop Beaujon, Clichy, France
[4] AP HP, Paris, France
[5] CHU Hop Ponchaillou, Rennes, France
[6] Intermune Inc, Brisbane, CA USA
[7] Biotrial, Rennes, France
[8] Ctr CAP, Montpellier, France
来源：
JOURNAL OF HEPATOLOGY | 2009年 / 50卷
关键词：
D O I：
10.1016/S0168-8278(09)60087-8
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
85
引用
收藏
页码：S35 / S35
页数：1
相关论文
共 50 条
  • [1] Antiviral Activity of Danoprevir (ITMN-191/RG7227) in Combination With Pegylated Interferon α-2a and Ribavirin in Patients With Hepatitis C
    Forestier, Nicole
    Larrey, Dominique
    Marcellin, Patrick
    Guyader, Dominique
    Patat, Alain
    Rouzier, Regine
    Smith, Patrick F.
    Qin, Xiaoli
    Lim, Sharlene
    Bradford, Williamson
    Porter, Steven
    Seiwert, Scott D.
    Zeuzem, Stefan
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2011, 204 (04): : 601 - 608
  • [2] In vitro synergistic antiviral activity of ITMN-191, an orally active inhibitor of the hepatitis C virus (HCV) NS3/4A protease, in combination with PEG-Interferon alfa-2A
    Tan, Hua
    Seiwert, Scott D.
    Blatt, Lawrence M.
    [J]. HEPATOLOGY, 2006, 44 (04) : 534A - 534A
  • [3] Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients
    Lawitz, Eric
    Rodriguez-Torres, Maribel
    Muir, Andrew J.
    Kieffer, Tara L.
    McNair, Lindsay
    Khunvichai, Ariya
    McHutchison, John G.
    [J]. JOURNAL OF HEPATOLOGY, 2008, 49 (02) : 163 - 169
  • [4] Peginterferon alfa-2a plus ribavirin for chronic hepatitis C
    Rakov, NE
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (03): : 259 - 260
  • [5] Peginterferon alfa-2a/ribavirin in hepatitis C virus patients nontolerant or nonresponsive to peginterferon alfa-2b/ribavirin
    Rustgi, V. K.
    Esposito, S.
    Hamzeh, F. M.
    Shiffman, M. L.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2008, 27 (05) : 433 - 440
  • [6] Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
    Fried, MW
    Shiffman, ML
    Reddy, KR
    Smith, C
    Marinos, G
    Goncales, FL
    Haussinger, D
    Diago, M
    Carosi, G
    Dhumeaux, D
    Craxi, A
    Lin, A
    Hoffman, J
    Yu, J
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (13): : 975 - 982
  • [7] Peginterferon alfa-2a plus ribavirin for hemophilic patients with chronic hepatitis C virus infection in Taiwan
    Lin, Jung-An
    Chen, Yeu-Chin
    Cheng, Shin-Nan
    Chen, Peng-Jen
    Chu, Heng-Cheng
    Hsieh, Tsai-Yuan
    Shih, Yu-Lueng
    [J]. JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2014, 113 (10) : 727 - 733
  • [8] Safety of peginterferon alfa-2a plus ribavirin in a large multinational cohort of chronic hepatitis C patients
    Lee, Samuel S.
    Roberts, Stuart K.
    Berak, Hanna
    Dusheiko, Geoffrey M.
    Harley, Hugh A.
    Gane, Edward J.
    Husa, Petr
    Horsmans, Yves J.
    Hadziyannis, Stephanos J.
    Heathcote, E. Jenny
    Messinger, Diethelm
    Tatsch, Fernando
    Han, Kwang-Hyub
    Ferenci, Peter
    [J]. LIVER INTERNATIONAL, 2012, 32 (08) : 1270 - 1277
  • [9] Peginterferon alfa-2a plus ribavirin for chronic hepatitis C - Reply
    Fried, MW
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (03): : 260 - 260
  • [10] Telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in chronic hepatitis C patients
    Zeuzem, Stefan
    [J]. JOURNAL OF HEPATOLOGY, 2008, 49 (02) : 157 - 159
12345